Mounjaro Tracker - log injections, weight, and side effects
Mounjaro is a once-weekly injection of tirzepatide. This page explains how to track a Mounjaro treatment with Dosley and links every medical fact to the FDA-approved label.
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medicine prescribed alongside diet and exercise to improve blood sugar in adults with type 2 diabetes. Because each treatment plan looks slightly different - different starting doses, titration schedules, and side-effect timelines - keeping a personal log helps you and your prescriber see how things are going. Dosley is a private tracker for your injections, weight changes, and side-effect notes. It is not a medical device and does not give medical advice. The information below summarises the publicly available FDA-approved label so the page sits next to your tracker rather than inside it. If anything here differs from what your clinician has told you, follow your clinician.
At a glance
- Active ingredient
- Tirzepatide 1
- Drug class
- GIP and GLP-1 receptor agonist 1
- Manufacturer
- Eli Lilly and Company 2
- FDA approval
- May 2022 (NDA 215866) 3
- Indication
- Adjunct to diet and exercise for type 2 diabetes in adults 1
- Schedule
- Once weekly, subcutaneous injection 1
- Starting dose
- 2.5 mg once weekly 1
- Maximum adult dose
- 15 mg once weekly 1
- Missed-dose window
- Within 4 days (96 hours) of the scheduled day 1
- Storage
- Refrigerated at 2–8°C; see the label for in-use room-temperature limits per pen format 1
Important safety information
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Mounjaro is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2. 1
Contraindications
Common side effects
Discuss benefits and risks with your healthcare provider before starting or continuing this medication.
Dosing and titration
Your prescriber decides every step on the schedule below. The summary here is for orientation while you log treatments - it is not a recommendation.
Treatment begins at 2.5 mg once weekly. After four weeks the prescriber may increase to 5 mg, then continue increasing in 2.5 mg increments after at least four weeks on the current dose, up to a maximum of 15 mg once weekly in adults. 1
The 2.5 mg starting amount is intended to help the body adjust before any glucose-lowering target is set. It is not the maintenance amount for most adults. 1
When you record a treatment in Dosley, you can attach the amount, the day, and any notes about how you tolerated it. The app does not change your schedule - it only records what your prescriber has set.
Injection sites and storage
Mounjaro is given by subcutaneous injection in the abdomen, thigh, or upper arm. Rotating sites between treatments is recommended in the prescribing information. 1
Pens should be kept refrigerated between 2°C and 8°C until first use. The room-temperature in-use period varies between the single-dose pen, multi-dose KwikPen, and vial formats - follow the limit printed on your packaging or in the patient leaflet. 1
Tracking injection sites and storage windows in Dosley is optional but useful - it gives you a quick view of which sites you have used recently and when a pen needs to be retired or moved.
Mounjaro and Zepbound
Mounjaro and Zepbound contain the same active ingredient. They are different brand names with different FDA-approved indications.
Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in adults who meet the indication criteria. Each brand has its own FDA-approved labeling, packaging, and patient leaflet. 1 3
Whether you have been prescribed one or the other is a question for your clinician. Dosley supports tracking either brand and treats them as separate treatments.
Missed dose
If a Mounjaro injection is missed, the FDA label allows it to be taken as soon as possible within 4 days (96 hours) of the scheduled day. After that window, skip the missed amount and resume on the next regular day. 1
About this medication and Dosley
How often is Mounjaro injected?
Mounjaro is a once-weekly subcutaneous injection. Your prescriber sets the day of the week and the amount; Dosley records what they have set so you can see your history. 1
What if I forget my Mounjaro on the scheduled day?
The FDA-approved label states the missed amount may be taken within 4 days (96 hours) of the scheduled day. After that window the missed amount is skipped and you wait until the next regular day. If you are unsure, contact your clinician. 1
What are the most common Mounjaro side effects?
In the FDA label's adverse-reaction tables, the most common side effects at the 15 mg amount were nausea (about 18%), diarrhea (about 17%), decreased appetite (about 11%), vomiting (about 9%), and constipation (about 7%). Logging side effects in Dosley helps you and your prescriber spot patterns. 1
Is Mounjaro the same molecule as Zepbound?
Yes. Both Mounjaro and Zepbound contain tirzepatide, but each has its own FDA approval and indication: Mounjaro is approved for type 2 diabetes and Zepbound is approved for chronic weight management. Speak to your clinician about which is appropriate for your situation. 3
Where is Mounjaro injected?
The label specifies subcutaneous injection in the abdomen, thigh, or upper arm, with site rotation. Dosley lets you tag the site for each entry so you can see at a glance where you have already injected. 1
How should Mounjaro be stored?
The FDA label says Mounjaro should be kept refrigerated between 2°C and 8°C until first use. The in-use room-temperature window depends on the pen format you have been dispensed - check the leaflet that came with your pen. 1
Does Dosley send my Mounjaro data to my clinic?
No. Dosley is a personal tracker. Your treatment log lives in your Dosley account, and you choose whether to export it as a PDF to share with your clinician. Talk to your healthcare team before changing anything in your treatment. 1
How Dosley supports a Mounjaro routine
Dosley is built for the small rituals of a once-weekly injection routine. The home screen shows your next scheduled day so you never have to count from the calendar, and a quick log entry takes about five seconds - pick the day, the amount you were prescribed, the site, and you are done.
Side-effect notes live next to each entry. Many people find that the early weeks of a new amount bring temporary changes in how they feel; logging those alongside the entry helps you and your prescriber see whether things are settling or whether the schedule needs adjusting.
Weight is tracked in the same place. Manual entry is two taps; a chart shows the trend rather than the daily noise, so a single bad-scale day does not break your week. If you use Apple Health, weight syncs automatically.
Pen tracking helps with the practical side. Dosley remembers which pen is open and how many uses are left, so you know when to fetch a new one from the fridge. Storage windows are reminders, not rules - always follow the leaflet that came with your medication.
Everything stays on your device unless you choose otherwise. There is no clinic dashboard, no advertiser, and no requirement to create an account. If your healthcare team asks for a summary, you can export a PDF from the app and share it on your terms.
Track your treatment with Dosley
Log injections, weights, and side effects in a private space designed for GLP-1 routines.
References
- 1. FDA-approved Mounjaro (tirzepatide) prescribing information (DailyMed)
- 2. Mounjaro USPI (Eli Lilly and Company)
- 3. Drugs@FDA: Mounjaro (NDA 215866)
Last reviewed:
Mounjaro is a registered trademark of Eli Lilly and Company. Dosley is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.